Clinical development of medicinal products intended for the treatment of chronic primary immune thrombocytopenia

  • Email
  • Help
Current effective version

Adopted guideline

Reference numberEMA/CHMP/153191/2013
Published28/03/2014
Effective from01/09/2014
KeywordsChronic primary immune thrombocytopenia, ITP, thrombopoietin receptor agonists
DescriptionThis document covers relevant aspects on the clinical studies to be conducted to assess the efficacy and safety of medicinal products intended for the treatment of chronic immune thrombocytopenia.


Document history

First version

Current version

Adopted guideline


Overview of comments


Draft guideline

In operation: 01/09/2014–present


Published: 28/03/2014


Published: 20/03/2013


Related content


How helpful is this page?

Average rating:

 Based on 0 ratings

Add your rating:

See all ratings
0 ratings
0 ratings
0 ratings
0 ratings
0 ratings
    

Tell us more